Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study

Vista senzilla d'ítem
dc.contributor.authorSanmartí Sala, Raimon
dc.contributor.authorInciarte-Mundo, Jose
dc.contributor.authorEstrada-Alarcon, Paula
dc.contributor.authorGarcia-Manrique, Maria
dc.contributor.authorNarváez García, Francisco Javier
dc.contributor.authorRodríguez Moreno, Jesús
dc.contributor.authorGomez-Centeno, Antoni
dc.contributor.authorPascal i Capdevila, Mariona
dc.contributor.authorYagüe, Jordi
dc.date.accessioned2017-05-03T10:54:53Z
dc.date.available2017-05-03T10:54:53Z
dc.date.issued2015-08
dc.date.updated2017-05-03T10:54:54Z
dc.descriptionArticle en format correspondència
dc.description.abstractWe read with great interest the paper by Chen et al1 analysing the relationship between therapeutic response to adalimumab and etanercept and serum drug trough levels in 70 patients with rheumatoid arthritis (RA). ...
dc.format.extent1 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec657895
dc.identifier.issn0003-4967
dc.identifier.urihttps://hdl.handle.net/2445/110383
dc.language.isoeng
dc.publisherBMJ Publishing Group
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1136/annrheumdis-2015-207530
dc.relation.ispartofAnnals of the Rheumatic Diseases, 2015, vol. 74, num. 8, p. e42
dc.relation.urihttps://doi.org/10.1136/annrheumdis-2015-207530
dc.rights(c) BMJ Publishing Group, 2015
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Ciències Clíniques)
dc.subject.classificationArtritis reumatoide
dc.subject.classificationMedicaments
dc.subject.classificationAdministració de medicaments
dc.subject.classificationSistema immunològic
dc.subject.classificationAnticossos monoclonals
dc.subject.otherRheumatoid arthritis
dc.subject.otherDrugs
dc.subject.otherAdministration of drugs
dc.subject.otherImmune system
dc.subject.otherMonoclonal antibodies
dc.titleTowards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Miniatura
Nom:
657895.pdf
Mida:
411.63 KB
Format:
Adobe Portable Document Format
Descarregar

Col·leccions

Articles publicats en revistes (Ciències Clíniques)